Blood flow indices by doppler ultrasonography vary with neoadjuvant chemotherapy but are not related to plasma VEGF levels in locally advanced breast cancer

Oncology

Volumn 71, Issue 3-4, 2007, Pages 185-189

  Öksüzoǧlu, Berna ^a,b   Vural, Murat ^a   Abali, Hüseyin ^a   Yilmaz, Mesude ^a   Yildirim, Nuriye ^a   Zengin, Nurullah ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Angiogenesis; Breast cancer, locally advanced; Doppler ultrasonography; Vascular endothelial growth factor

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD FLOW; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; HEART CYCLE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; SYSTOLE; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD FLOW VELOCITY; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; ULTRASONOGRAPHY, DOPPLER, COLOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548058629     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106067     Document Type: Article

References (22)

1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
2. Moskovic EC, Mansi JL, King DM, Murch JR, Smith IE: Mammography in the assessment of response to medical treatment of large primary breast cancers. Clin Radiol 1993;47:339-344.
3. Lagalla R,Caruso G, Finazzo M: Monitoring treatment response with color and power Doppler. Eur J Radiol 1998;28:149-156.
4. Abali H, Abali GK: Angiogenesis and antiangiogenesis in neoplastic and non-neoplastic diseases; in Zubar RV (ed): New Angiogenesis Research. New York, Nova Science Publishers, 2005, pp 235-255.
5. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HE, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
6. Kilickap S, Abali H, Celik I: Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542.
7. Huber S, Medl M, Helbich T, Taucher S, Wagner T, Rudas M, Zuna I, Delorme S: Locally advanced breast carcinoma: computer assisted semiquantitative analysis of color Doppler ultrasonography in the evaluation of tumor response to neoadjuvant chemotherapy (work in progress). J Ultrasound Med 2000;19:601-607.
8. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC: Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology 1994;190:825-830.
9. Folkman J: Tumor angiogenesis; in Bast RC, Kufe DW, Pollock RE, Weichselbaum R, Holland JF, Frei E (eds): Cancer Medicine, ed 5. Hamilton, Decker, 2000, pp 132-152.
10. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000;5(suppl 1):37-44.
11. Morabito A, Sarmiento R, Bonginelli P, Gasparini G: Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol Hematol 2004;49:91-107.
12. Rugo HS: Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004;9(suppl 1):43-49.
13. Chao TC, Lo YF, Chen SC, Chen MF: Color Doppler ultrasound in benign and malignant breast tumors. Breast Cancer Res Treat 1999;57:193-199.
14. Hayashi N, Miyamoto Y, Nakata N, Irie T, Ikegami M, Asao K, Tada S: Breast masses: color Doppler, power Doppler, and spectral analysis findings. J Clin Ultrasound 1998;26:231-238.
15. Peters-Engl C, Medl M, Leodolter S: The use of color-coded and spectral Doppler ultrasound in the differentiation of benign and malignant lesions. Br J Cancer 1995;72:137-139.
16. Lee W-J, Chu J-S, Huang C-S, Chang M-F, Chang K-J, Chen K-M: Breast cancer vascularity: color Doppler sonography and histopathology study. Breast Cancer Res Treat 1996;37:291-298.
17. Giovagnorio F, Rusticali A, Araneo AL: Color and pulsed Doppler evaluation of benign and malignant adenopathy. Clin Imaging 1997;21:163-169.
18. Kurosomi M: Significance of histopathological evaluation in primary therapy for breast cancer - recent trends in primary nodality with pathological complete response (pCR) as endpoint. Breast Cancer 2004;11:139-147.
19. Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A: Color Doppler ultrasound as an objective tool for chemotherapeutic response in advanced breast cancer. Breast Cancer 2005;12:45-51.
20. Boonjunwetwat D, Prueksadee J, Sampatanukul P, Chatamra K: Does color Doppler ultrasound vascularity predict the response to neoadjuvant chemotherapy in breast cancer? J Med Assoc Thai 2005;88:1367-1372.
21. Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, Badve S, Storniolo A, Goulet R, Sledge GW Jr: Randomized phase II trial of the anti-angiogenic potentials of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 2005;89:187-197.
22. Kim SW, Park SS, Ahn SJ, Chung KW, Moon WK, Im JG, Yeo JS, Chung JK, Noh DY: Identification of angiogenesis in primary breast carcinoma according to the image analysis. Breast Cancer Res Treat 2002;74:121-129.